beta
/540O Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): Results from phase II part of FRUSICA-2

Reviews

Join the dialogue

Submit a peer review to improve the scientific record

Summary